Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

Journal of Allergy and Clinical Immunology

Volumn 109, Issue 3, 2002, Pages 547-555

  Reitamo, Sakari ^a   Rustin, Malcolm ^b   Ruzicka, Thomas ^c   Cambazard, Frédéric ^d   Kalimo, Kirsti ^e   Friedmann, Peter S ^f   Schoepf, Erwin ^g   Lahfa, Mourad ^h   Diepgen, Thomas L ⁱ   Judodihardjo, Harryono ^j   Wollenberg, Andreas ^k   Berth Jones, John ^l   Bieber, Thomas ^m  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d HÔPITAL NORD   (France)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^g UNIVERSITY OF FREIBURG   (Germany)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^j CARDIFF UNIVERSITY   (United Kingdom)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l WALSGRAVE HOSPITAL   (United Kingdom)

^m UNIVERSITY OF BONN   (Germany)

more..

Author keywords

Atopic dermatitis; Efficacy; FK506; Ointment; Safety; Tacrolimus; Topical

Indexed keywords

HYDROCORTISONE BUTYRATE; TACROLIMUS;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OINTMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SKIN IRRITATION;

EID: 0036130451     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.121832     Document Type: Article

References (29)

1. Atopic dermatitis: New insights and opportunities for therapeutic intervention
2. Disease management of atopic dermatitis: A practice parameter
3. Topical treatment with corticosteroids
4. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis
5. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes
6. Human epidermal Langerhans cells are targets for the immunosuppressive macrolide tacrolimus (FK506)
7. Topical tacroilmus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen presenting dendritic cells in atopic dermatitis
8. Anti-inflammatory effect of FK506 on human skin mast cells
9. Tacrolimus: A topical immunomodulatory therapy for atopic dermatitis
10. A short-term trial of tacrolimus ointment for atopic dermatitis
11. A randomized, vehicle-controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children
12. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy
13. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
14. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety
15. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis
16. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children
17. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial
18. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions
19. Tacrolimus (FK506) ointment for atopic dermatitis: A phase I study in adults and children
20. Diagnostic features of atopic dermatitis
21. Grading of the severity of atopic dermatitis
22. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis
23. Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis
24. Phase III comparative study of FK506 ointment versus betamethasone valerate ointment in atopic dermatitis (trunk/extremities)
25. Clinical trial comparing hydrocortisone-17-butyrate to betamethasone-valerate in a series of patient with eczematous skin lesions
26. Assessment of the atrophogenicity potential of corticosteroids by ultrasound and by epidermal biopsy under occlusive and nonocclusive conditions
27. Comparison of the effect of hydrocortisone, hydrocortisone- 17-butyrate and betamethasone on collagen synthesis in human skin in vivo
28. Topical glucocorticoids with improved benefit/risk ratio: Do they exist?